Canon Medical Systems USA has secured approval from the US Food and Drug Administration (FDA) for its new MR system, the Vantage Galan 3T XGO Edition.
The system, which features Saturn X Gradient, is said to offer up to 30% improved signal-to-noise ratio (SNR) for brain diffusion weighted imaging (DWI).
It allows sequences for quantitative analysis and enables to finish cardiac exams with lesser breath holds and enhanced patient comfort.
With the support of PURERF and Saturn technologies, the system will quickly capture quality neuro imaging exams.
According to the company, the system helps health care providers to produce higher resolution images for myriad neuro exams within five minutes.
The system also includes MultiBand Speeder technology that enables to capture multiple slices at the same time, helping to reduce diffusion weighted imaging scan times by up to two times
Canon’ Galan 3T XGO Edition also includes T1 mapping capability, which uses modified look-locker inversion recovery (MOLLI) sequence and enables providers to capture more quantitative characterization of myocardial tissue within a single breath hold.
Its phase sensitive inversion recovery (PSIR) capability in the heart will help to offer improved contrast in late-enhanced imaging and avoids the need for inversion time (TI) calibration scan.
Canon Medical Systems USA CT, PET/CT and MR business units senior director Dominic Smith said: “The new Galan 3T XGO Edition with Saturn X Gradient builds on the strengths of its predecessor and expands the versatility of MR even further with faster and higher resolution images, so that physicians don’t have to sacrifice accuracy or patient comfort for speed.”
Image: Canon’s Vantage Galan 3T XGO Edition with Saturn X Gradient technology. Photo: courtesy of Canon Medical Systems, USA.